×
  • 業(ye) 務谘詢

    中國:

    Email: marketing@boboandtiantian.com

    業(ye) 務谘詢專(zhuan) 線:400-780-8018

    (僅(jin) 限服務谘詢,其他事宜請撥打川沙總部電話)

    川沙總部電話: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心

設計合成一係列DHODH抑製劑作為潛在的類風濕性關節炎治療藥物,PK研究通過必威betway网址進行

2023-06-28
|
訪問量:

15-DHODH (1).jpg

Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents. The most potent compound 54 displays favorable pharmacokinetic (PK) profiles in vivo.

The PK study was conducted by using Medicilon's preclinical pharmacokinetic study services.

Reference

相關新聞
×
搜索驗證
點擊切換